Novel therapeutic strategies for patients with metastatic triple-negative breast cancer
Triple-negative breast cancer (TNBC) remains the most aggressive subtype of breast cancer. In the presence of distant metastases, the median overall survival does not exceed 14 months. TNBC is an extremely heterogeneous group of tumors, it includes both tumors extremely sensitive to chemotherapy and...
Guardado en:
Autores principales: | Inna P. Ganshina, Olga O. Gordeeva, Mariam Sh. Manukian |
---|---|
Formato: | article |
Lenguaje: | RU |
Publicado: |
IP Habib O.N.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/a99aa8bbbad543218bc93d48c8adcbf6 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Opportunities for metastatic triple negative breast cancer therapy
por: Inna P. Ganshina, et al.
Publicado: (2021) -
Antiangiogenic therapy for breast cancer with triple negative phenotype
por: Inna P. Ganshina, et al.
Publicado: (2021) -
Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. Current Scenario and Future Perspectives
por: Giacomo Barchiesi, et al.
Publicado: (2021) -
Current advances in biomarkers for targeted therapy in triple-negative breast cancer
por: Fleisher B, et al.
Publicado: (2016) -
Triple-negative breast cancer: treatment challenges and solutions
por: Collignon J, et al.
Publicado: (2016)